Our colleagues at The Ohio State University Comprehensive Cancer Center have send us this information about a new clinical trial specifically for Lynch syndrome patients.
We are excited to announce that we have opened a research study at The Ohio State University looking at the effects of a PD-1 inhibitor drug, Nivolumab (also known as immunotherapy), to prevent colon adenomas in individuals with Lynch syndrome. Lynch syndrome patients are at increased risk of developing colon cancers that have a change called microsatellite instability. Tumors with microsatellite instability have a high response rate to treatment with PD-1 inhibitors. This study will investigate for the first time the use of PD-1 inhibitors to prevent these cancers and precancers. In order to be eligible for this study, individuals must have a germline mutation in the MLH1 or MSH2 genes and a history of colon cancer with partial removal of their colon. This clinical trial is listed at www.clinicaltrials.gov with ID # NCT03631641. If you are interested in obtaining additional information about participating in this study, please contact the study coordinator for OSU 17198, Shona Taylor, at ) 614-685-4337 or shona.taylorl@osumc.edu, or the James Direct Line at 1-800-293-5066.